You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天邦股份(002124.SZ)擬5.1億元出售成都天邦及南京史紀100%股權
格隆匯 03-15 20:58

格隆匯 3 月 15日丨天邦股份(002124.SZ)公佈,公司(“轉讓方”)於2021年3月15日經第七屆董事會第三十二次會議審議通過《關於轉讓子公司股權的議案》,擬將成都天邦生物製品有限公司(“成都天邦”)100%股權和南京史紀生物科技有限公司(“南京史紀”)100%股權出售給賢豐控股股份有限公司(“賢豐控股”)和深圳市宏屹投資發展有限公司(“宏屹投資”)(“受讓方”)。此次交易完成後,上市公司疫苗生產業務將全部剝離,不影響上市公司其他業務的正常經營。

賢豐控股購買成都天邦70%股權和南京史紀70%股權,交易對價分別為3.22億元和3500萬元,宏屹投資購買成都天邦30%股權和南京史紀30%股權,交易對價分別為1.38億元和1500萬元。

公司此次出售成都天邦和南京史紀,剝離公司的疫苗業務,主要是出於以下考慮:

集中資源,更加聚焦於生豬養殖和肉製品產業。公司生豬養殖業務正處於快速擴規模的階段,固定資產投資和生豬存欄大幅增加,生豬產業鏈向下遊屠宰和深加工延申,都需要大量的資金投入。公司自 2008年進入疫苗業務以來,疫苗業務的增長較慢,在公司營業收入中的佔比很小。出售疫苗業務可以回收部分資金用於公司生豬養殖和肉製品業務。

出售疫苗業務並不會影響公司生豬養殖業務的疫苗供應,雙方仍可以在業務上以市場化方式保持密切合作。疫苗業務的部分存量客户和潛在客户也是公司的同行或者競爭對手,出售以後更有利於疫苗業務的獨立發展,開發更多的外部業務,在市場競爭中進一步挖掘潛力發展壯大,將來公司也會多一個更為優質的疫苗供應商可供選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account